185750 — Chong Kun Dang Pharmaceutical Share Price
0.000.00%
Last trade - 00:00- KR₩1tn
- KR₩934bn
- KR₩2tn
- 77
- 64
- 27
- 60
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.92 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -11.13% | ||
| Dividend Yield (f) | 1.25% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.17 | ||
| Price to Tang. Book | 1.28 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.66 | ||
| EV to EBITDA | 6.76 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.04% | ||
| Return on Equity | 12.76% | ||
| Operating Margin | 6.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 1,303,005.52 | 1,343,559.36 | 1,488,344.73 | 1,669,404.44 | 1,586,430.8 | 1,681,115 | 1,774,250 | 8.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +68.15 | -53.11 | +100.28 | +154.62 | -50.33 | -16.96 | +4.75 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chong Kun Dang Pharmaceutical Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The company sells products in domestic and overseas markets.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 5th, 2013
- Public Since
- December 6th, 2013
- No. of Shareholders
- 36,918
- No. of Employees
- 1,904
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 13,216,631
- Address
- 8, Chungjeong-ro, Seodaemun-gu, SEOUL, 03742
- Web
- https://www.ckdpharm.com/
- Phone
- +82 221940300
- Auditors
- Deloitte Anjin LLC
Upcoming Events for 185750
Q2 2025 Chong Kun Dang Pharmaceutical Corp Earnings Release
Similar to 185750
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
Daewon Pharmaceutical Co
Korea Exchange - KSE
FAQ
What is the Chong Kun Dang Pharmaceutical share price?
As of Today at 19:57 UTC, shares in Chong Kun Dang Pharmaceutical are trading at KR₩79,100. This share price information is delayed by 15 minutes.
How has the Chong Kun Dang Pharmaceutical share price performed this year?
Shares in Chong Kun Dang Pharmaceutical last closed at KR₩79,100 and the price had moved by -16.28% over the past 365 days. In terms of relative price strength the Chong Kun Dang Pharmaceutical share price has underperformed the FTSE Developed Asia Pacific Index by -13.89% over the past year.
What are the analyst and broker recommendations for Chong Kun Dang Pharmaceutical?
The overall consensus recommendation for Chong Kun Dang Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Chong Kun Dang Pharmaceutical dividend yield?
The Chong Kun Dang Pharmaceutical dividend yield is 1.32% based on the trailing twelve month period.
Does Chong Kun Dang Pharmaceutical pay a dividend?
Last year, Chong Kun Dang Pharmaceutical paid a total dividend of KR₩1,048, and it currently has a trailing dividend yield of 1.32%. We do not have any data on when Chong Kun Dang Pharmaceutical is to next pay dividends.
When does Chong Kun Dang Pharmaceutical next pay dividends?
We do not have data on when Chong Kun Dang Pharmaceutical is to next pay dividends. The historic dividend yield on Chong Kun Dang Pharmaceutical shares is currently 1.32%.
How do I buy Chong Kun Dang Pharmaceutical shares?
To buy shares in Chong Kun Dang Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chong Kun Dang Pharmaceutical?
As of the previous close price of KR₩79,100, shares in Chong Kun Dang Pharmaceutical had a market capitalisation of KR₩1tn.
Where are Chong Kun Dang Pharmaceutical shares listed?
Here are the trading details for Chong Kun Dang Pharmaceutical:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 185750
What kind of share is Chong Kun Dang Pharmaceutical?
Based on an overall assessment of its quality, value and momentum Chong Kun Dang Pharmaceutical is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chong Kun Dang Pharmaceutical share price forecast for 2025?
The analyst consensus target price for shares in Chong Kun Dang Pharmaceutical is KR₩124,200. That is 57.02% above the last closing price of KR₩79,100.
Analysts covering Chong Kun Dang Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of KR₩6,542 for the next financial year.
Find out moreWhat is the trend in the Chong Kun Dang Pharmaceutical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chong Kun Dang Pharmaceutical. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -16.43%.
As of the last closing price of KR₩79,100, shares in Chong Kun Dang Pharmaceutical were trading -16.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chong Kun Dang Pharmaceutical PE Ratio?
The Chong Kun Dang Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 11.92. The shares last closed at KR₩79,100.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chong Kun Dang Pharmaceutical?
Chong Kun Dang Pharmaceutical's management team is headed by:
- Gi Won Kim - DRC